Solvay licenses Depomed's gabapentin GR in Central and North America
Belgian drugmaker Solvay Pharmaceuticals has licensed USA-based Depomed's gastric-retentive formulation of gabapentin which is designed to reduce the dose frequency and side effects of the postherpetic neuralgia drug.
Under the terms of the deal, which covers rights to sell the Phase III-stage drug candidate in the USA, Canada, Mexico and Puerto Rico, Solvay will pay $25.0 million up front and will make payments subject to the fulfilment of future regulatory and sales milestones worth up to $370.0 million in total, as well as royalties.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze